Hadasit Bio-Holdings Ltd
HBL - Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It operates in the fields of oncology, regenerative medicine, and inflammatory disease. The company develops biological drugs; and plasma RNA biomarkers for colorectal cancer. It offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. HBL - Hadasit Bio-Holdings L… Read more
Hadasit Bio-Holdings Ltd (HSITF) - Total Liabilities
Latest total liabilities as of June 2024: $2.71 Million USD
Based on the latest financial reports, Hadasit Bio-Holdings Ltd (HSITF) has total liabilities worth $2.71 Million USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hadasit Bio-Holdings Ltd - Total Liabilities Trend (2012–2023)
This chart illustrates how Hadasit Bio-Holdings Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hadasit Bio-Holdings Ltd Competitors by Total Liabilities
The table below lists competitors of Hadasit Bio-Holdings Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EXLSERVICE HLDG
BE:LHV
|
Germany | €702.27 Million |
|
Amanet Management & Systems Ltd
TA:AMAN
|
Israel | ILA61.99 Million |
|
Maximus Resources Ltd
AU:MXR
|
Australia | AU$2.47 Million |
|
Quality Distribution Inc
NASDAQ:QLTY
|
USA | $435.93 Million |
|
Bkm Industries Limited
NSE:BKMINDST
|
India | ₹253.27 Million |
Liability Composition Analysis (2012–2023)
This chart breaks down Hadasit Bio-Holdings Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.97 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hadasit Bio-Holdings Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hadasit Bio-Holdings Ltd (2012–2023)
The table below shows the annual total liabilities of Hadasit Bio-Holdings Ltd from 2012 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $2.13 Million | -45.10% |
| 2022-12-31 | $3.88 Million | +436.84% |
| 2021-12-31 | $722.00K | -83.10% |
| 2020-12-31 | $4.27 Million | +9.23% |
| 2019-12-31 | $3.91 Million | +278.61% |
| 2018-12-31 | $1.03 Million | -86.78% |
| 2017-12-31 | $7.81 Million | -0.32% |
| 2016-12-31 | $7.84 Million | -5.69% |
| 2015-12-31 | $8.31 Million | -19.38% |
| 2014-12-31 | $10.31 Million | +4.41% |
| 2013-12-31 | $9.87 Million | +34.76% |
| 2012-12-31 | $7.33 Million | -- |